Elicio Therapeutics Q2 FY26 net loss narrows to $8.2 million; loss per share improves to $0.43
ELTX•Second-quarter results
- Second-quarter net loss narrowed to $8.2 million; loss per share improved to $0.43.
- R&D expense dipped to $6.8 million on lower clinical trial costs; G&A expense climbed to $3.6 million.
Cash position and pipeline update
- Cash and cash equivalents totaled $23.5 million as of June 30, 2026; July financing raised $15 million gross.
- Cash runway is expected into Q1 2027.
- The Phase 1 ELI-002 7P combination study in metastatic pancreatic cancer is targeted to start in Q4 2026.
